Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Bioorg Med Chem. 2022 Oct 4;73:117043. doi: 10.1016/j.bmc.2022.117043

Table 1.

Compounds tested in NB SH-SY5Y and SK-N-AS, and fibrosarcoma HT-1080. Blank: not tested NA: Ambiguous fit.

Structure Compound Average IC50
SH-SY5Y		 Average IC50
SK-N-AS		 Average IC50
HT-1080
graphic file with name nihms-1864211-t0003.jpg Pyronaridine 1.70 μM 3.45 μM 4.23 μM
graphic file with name nihms-1864211-t0004.jpg 12126040 1.20 μM 3.86 μM 3.6 μM
graphic file with name nihms-1864211-t0005.jpg 12126036 NA NA NA
graphic file with name nihms-1864211-t0006.jpg 12126038 3.41 μM 5.40 μM 6.09 μM
graphic file with name nihms-1864211-t0007.jpg 12126039 9.70 μM NA 13.77 μM
graphic file with name nihms-1864211-t0008.jpg 12126035 Drug did not inhibit at 5 μM NA NA
graphic file with name nihms-1864211-t0009.jpg 12126037 Drug did not inhibit at 5 μM NA NA
graphic file with name nihms-1864211-t0010.jpg 12126072 Drug did not inhibit at 5 μM NA NA
graphic file with name nihms-1864211-t0011.jpg 10326099 Drug did not inhibit at 5 μM NA NA
graphic file with name nihms-1864211-t0012.jpg Quinacrine 8.57 μM NA 29.1 μM
graphic file with name nihms-1864211-t0013.jpg Crizotinib 0.92 μM 12.12 μM NA